NanoViricides, Inc. (the “Company”) reported today that it has signed a “confidential disclosure agreement” (“CDA”) with Viroclinics Biosciences, BV (“Viroclinics”), a spinoff of the Department of Viroscience at the Erasmus Medical Centre (“Erasmus”) in Rotterdam, the Netherlands.
The agreement will allow the scientists at Viroclinics to develop a specific proposal for the testing of different nanoviricides® , such as FluCide™, against viruses of mutual interest to both organizations.
Viroclinics is a virology contract research organization serving the biopharmaceutical community. Viroclinics provides preclinical as well as clinical development services for vaccines and antivirals. The ongoing, intimate interaction between scientists at Erasmus and Viroclinics staff yields a strong, flourishing platform to create and implement assays at the forefront of viroscience. Viroclinics participated in the discovery and characterization of the Middle East Respiratory Syndrome (MERS) Coronavirus in 2013 and SARS Coronavirus in 2003, attesting to its leadership position in the field.
NanoViricides, Inc. anticipates that we will be able to test and develop our drug candidates against influenzas, dengue, MERS Coronavirus, as well as rabies, with the help of Viroclinics. In particular, NanoViricides is interested in the testing of its lead broad-spectrum anti-influenza drug candidate FluCide against various influenza A strains including the highly lethal H5N1 and H7N9 viruses that pose a strong global public health threat.
Testing of nanoviricides antiviral drug candidates will be performed in a BSL2 or BSL3 facility at Viroclinics, as applicable. These facilities are designed to contain and enable the safe handling of organisms that can pose a significant threat to health. Executives from NanoViricides plan to visit the Rotterdam facility later this month to conclude the final research agreement.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.